Combined Positron Emission Tomography/Computed Tomography in Sunitinib Therapy Assessment of Patients with Metastatic Renal Cell Carcinoma

Revheim, Mona-Elisabeth; Winge-Main, Anna K; Hagen, Gaute; Fjeld, Jan Gunnar; Fosså, Sophie D.; Lilleby, Wolfgang

doi:10.1016/j.clon.2010.11.006

Cited by 42 publications

(38 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SUV provides highly reproducible parameters of tumor glucose utilization but unfortunately, there is no cut-off value that would be specific for RCC. Values can diverge from undetectable (below 1.5) to levels over 24.0 (17,18). Regarding the cell subtype of RCC, no correlation in SUV values was found (19).…”

Section: Fdg Pet/ct In Evaluation and Staging Of Rcc Patientsmentioning

confidence: 60%

“…This is due to the existence of physiologic activity in the renal collecting system, which mimics activity in smaller lesions nearby. Patients with RCC tumors presenting with high SUVmax index have poor prognosis and survival rate of the patients with SUVmax value higher than 8.8 was the lowest (17,18). FDG was proved to be highly sensitive for metastatic lesions of RCC.…”

Section: Fdg Pet/ct In Evaluation and Staging Of Rcc Patientsmentioning

confidence: 96%

See 1 more Smart Citation

PET/CT in renal and bladder cancers

Balenović¹,

Mihaïlovic²,

Jazvić³

et al. 2012

Arch Oncol

View full text Add to dashboard Cite

FDG is the most frequently used positron emission tomography probe but it has certain limitations when used in urological cancers due to its urinary elimination, which prevents the proper visualization of the bladder and kidneys. The introduction of co-registered PET and computed tomography (PET/CT) represents a major advance in technology and now become the new standard for many cancers. For the staging and surveillance of renal cell cancer, FDG PET/ CT had results that were at least as good as conventional methods, which are potentially harmful for the remained renal function. FDG-PET/CT is able to evaluate early response to sunitinib or sorafenib treatment in metastatic renal cell cancer. An early decrease in the mean glucose uptake was found in both soft and skeletal lesions after treatment, thus PET seems to be more advantageous compared with RECIST evaluation. In addition, the survival of patients with advanced renal cell cancer can be predicted by evaluating their SUVmax using FDG-PET/CT. Although urinary bladder cancer demonstrates sufficiently increased FDG uptake, primary tumors are difficult to identify due to the renal excretion of FDG. The accuracy of FDG-PET/CT in metabolically active metastases is generally higher when compared to conventional CT except for identifying small lung deposits. PET/CT with delayed images after a diuretic and oral hydration may improve detection of locally recurrent or residual UBC and could replace standard CT and bone scintigraphy in the presurgical staging and monitoring of patients with urinary bladder cancer. 18F-choline PET may be useful for staging of urinary bladder cancer in addition to FDG PET

show abstract

Section: Fdg Pet/ct In Evaluation and Staging Of Rcc Patientsmentioning

confidence: 60%

Section: Fdg Pet/ct In Evaluation and Staging Of Rcc Patientsmentioning

confidence: 96%

PET/CT in renal and bladder cancers

Balenović¹,

Mihaïlovic²,

Jazvić³

et al. 2012

Arch Oncol

View full text Add to dashboard Cite

show abstract

“…The authors concluded that PET-CT has potential value for evaluating early treatment response to TKIs in mRCC and in predicting PFS; however, further studies are needed to verify these findings [62]. In a recent study, Revheim et al [63] evaluated the clinical benefit of PET-CT in mRCC treated with sunitinib and concluded that high baseline FDG uptake indicates aggressive disease and that the degree of reduction in FDG uptake after sunitinib treatment adds valuable prognostic information.…”

Section: Positron Emission Tomographymentioning

confidence: 94%

Evaluation of Treatment Response in Patients with Metastatic Renal Cell Carcinoma: Role of State-of-the-Art Cross-Sectional Imaging

et al. 2011

View full text Add to dashboard Cite

Recent advances in genetics and oncology have led to development of a wide array of molecular therapeutics in the management of patients with metastatic renal cell carcinoma. These drugs have revolutionized the treatment of advanced disease by significantly improving patient outcomes. State-of-the-art cross-sectional imaging techniques play a seminal role in the evaluation of treatment response by providing reproducible, objective data, thereby permitting accurate quantification of tumor burden. Evolving functional imaging techniques such as perfusion and diffusion studies continue to advance the technology beyond assessing changes in tumor size and morphology.

show abstract

“…In another prospective study [32] , the sensitivity of FDG-PET for the detection of distant metastasis from RCC was more modest, mostly due to the small size of the metastasis. In a prospective study of 14 patients with mRCC treated with sunitinib, it was found that PFS correlated with the baseline standardized uptake value [33] , and when mRCC shows increased uptake of FDG, PET may play a role in the response evaluation of targeted therapy.…”

Section: Positron Emission Tomographymentioning

confidence: 99%

Metastatic renal cell cancer

Rasmussen¹

2013

Cancer Imaging

View full text Add to dashboard Cite

Targeted therapy is the treatment of choice in patients with metastatic renal cell cancer (mRCC) at most institutions although a combination of cytokine therapy and targeted therapy still is being investigated. Morphological size-based criteria (RECIST) has failed in monitoring the effect of targeted therapy in patients with mRCC, as successful therapy often does not result in a decrease in tumour size. Modifications of size-based criteria and criteria based on computed tomography (CT) contrast enhancement has been introduced. Different imaging modalities that rely on characteristics other than size such as dynamic contrast-enhanced (DCE) ultrasonography, DCE CT, DCE magnetic resonance imaging (MRI), diffusion-weighted MRI, positron emission tomography and texture analysis seem to contribute with prognostic information, even at baseline scans, and can predict tumour response early after initiating therapy. No new standard for the imaging follow-up of targeted therapy in mRCC has been established.

show abstract

Combined Positron Emission Tomography/Computed Tomography in Sunitinib Therapy Assessment of Patients with Metastatic Renal Cell Carcinoma

Cited by 42 publications

References 16 publications

PET/CT in renal and bladder cancers

PET/CT in renal and bladder cancers

Evaluation of Treatment Response in Patients with Metastatic Renal Cell Carcinoma: Role of State-of-the-Art Cross-Sectional Imaging

Metastatic renal cell cancer

Contact Info

Product

Resources

About